Abstract B015: Combinatorial genetic screens to map synthetic lethal interactions and identify new cancer drug targets in KRAS mutant cancers

IF 5.3 2区医学 Q1 ONCOLOGY

Molecular Cancer Therapeutics Pub Date : 2024-06-10 DOI:10.1158/1538-8514.synthleth24-b015

Rand Arafeh, Laura Chang, Lydia Sawyer, Helen Wang, James McFarland, Joshua Dempster, Peter C. DeWeirdt, John G Doench, William C Hahn

引用次数: 0

Abstract

This abstract is being presented as a short talk in the scientific program. A full abstract is printed in the Proffered Abstracts section (PR014) of the Conference Program/Proceedings. Citation Format: Rand Arafeh, Laura Chang, Lydia Sawyer, Helen Wang, James McFarland, Joshua Dempster, Peter DeWeirdt, John Doench, William C Hahn. Combinatorial genetic screens to map synthetic lethal interactions and identify new cancer drug targets in KRAS mutant cancers [abstract]. In: Proceedings of the AACR Special Conference in Cancer Research: Expanding and Translating Cancer Synthetic Vulnerabilities; 2024 Jun 10-13; Montreal, Quebec, Canada. Philadelphia (PA): AACR; Mol Cancer Ther 2024;23(6 Suppl):Abstract nr B015.

查看原文本刊更多论文

摘要 B015：通过组合遗传筛选绘制合成致死相互作用图并确定 KRAS 突变癌症的新抗癌药物靶点

本摘要将作为科学会议日程中的简短发言。完整摘要刊载于大会日程/论文集的 "提供摘要 "部分 (PR014)。引用格式：Rand Arafeh, Laura Chang, Lydia Sawyer, Helen Wang, James McFarland, Joshua Dempster, Peter DeWeirdt, John Doench, William C Hahn.通过组合遗传筛选绘制合成致死相互作用图并确定 KRAS 突变癌症的新抗癌药物靶点 [摘要].In：AACR 癌症研究特别会议论文集：扩大和转化癌症合成弱点；2024 年 6 月 10-13 日；加拿大魁北克省蒙特利尔。费城（宾夕法尼亚州）：AACR; Mol Cancer Ther 2024;23(6 Suppl):Abstract nr B015.

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Molecular Cancer Therapeutics 医学-肿瘤学

CiteScore

11.20

自引率

1.80%

发文量

331

审稿时长

3 months

期刊介绍： Molecular Cancer Therapeutics will focus on basic research that has implications for cancer therapeutics in the following areas: Experimental Cancer Therapeutics, Identification of Molecular Targets, Targets for Chemoprevention, New Models, Cancer Chemistry and Drug Discovery, Molecular and Cellular Pharmacology, Molecular Classification of Tumors, and Bioinformatics and Computational Molecular Biology. The journal provides a publication forum for these emerging disciplines that is focused specifically on cancer research. Papers are stringently reviewed and only those that report results of novel, timely, and significant research and meet high standards of scientific merit will be accepted for publication.